Cargando…

The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV

BACKGROUND: In the United States, a disproportionate number of persons with HIV (PWH) and opioid use disorder (OUD) are involved in the justice system. Medications for OUD (MOUD) can reduce convictions and incarceration time in persons with OUD. Extended-release naltrexone (XR-NTX) has been shown to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parchinski, Kaley, Di Paola, Angela, Wilson, Allison P., Springer, Sandra A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Full Length Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163604/ https://www.ncbi.nlm.nih.gov/pubmed/37159815 http://dx.doi.org/10.1016/j.dadr.2023.100159

Ejemplares similares

Naltrexone extended-release injection: an option for the management of opioid abuse
por: Taylor, Robert, et al.
Publicado: (2011)

Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone
por: Marciuch, Anne, et al.
Publicado: (2023)

The opioid antagonist naltrexone decreases seizure‐like activity in genetic and chemically induced epilepsy models
por: Sturgeon, Morgan L., et al.
Publicado: (2021)

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
por: Nunes, Edward V., et al.
Publicado: (2015)

COVID-19 impact on opioid overdose after jail release in Massachusetts
por: Friedmann, Peter D., et al.
Publicado: (2023)

Medication Treatment for Opioid Use Disorders:: A Brief Overview with Comments on Extended Release Naltrexone
por: Woody, George
Publicado: (2017)

Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study
por: O'Kelly, Brendan, et al.
Publicado: (2022)

Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
por: Earley, Paul H., et al.
Publicado: (2017)

Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis
por: Hoffman, Kim A., et al.
Publicado: (2021)

Association between contact with mental health and substance use services and reincarceration after release from prison
por: Thomas, Emma G., et al.
Publicado: (2022)

Epidemiologic and Molecular Pathophysiology of Chronic Opioid Dependence and the Place of Naltrexone Extended-Release Formulations in its Clinical Management
por: Reece, Albert Stuart
Publicado: (2012)

Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018
por: Jain, Priya, et al.
Publicado: (2020)

Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone
por: Karlsson, Ann Tarja, et al.
Publicado: (2022)

Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence
por: Li, Xinyi, et al.
Publicado: (2023)

Association of Mental Health Services Access and Reincarceration Among Adults Released From Prison in British Columbia, Canada
por: Palis, Heather, et al.
Publicado: (2022)

Whose mu fared better? The effect of extended-release naltrexone (XR-NTX) on treatment outcomes for opioid and alcohol users
por: Crèvecoeur-MacPhail, Desirée A
Publicado: (2015)

Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence
por: Wang, A-L, et al.
Publicado: (2015)

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
por: Velasquez, Melissa, et al.
Publicado: (2019)

1313. Complementary Effects of Medical Follow-up and Virologic Suppression for Reincarcerated Inmates Living with HIV
por: Badowski, Melissa E, et al.
Publicado: (2019)

Medicaid expansion and opioid supply policies to address the opioid overdose crisis
por: Shakya, Shishir, et al.
Publicado: (2022)

Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
por: Comer, Sandra D., et al.
Publicado: (2020)

Naltrexone Implant for Opioid Use Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021)

Physically Targeted Intravenous Polyurethane Nanoparticles for Controlled Release of Atorvastatin Calcium
por: Eftekhari, Behnaz Sadat, et al.
Publicado: (2017)

A qualitative exploration of the eight dimensions of wellness in opioid use disorder recovery during the postpartum period
por: Mallahan, Stephanie, et al.
Publicado: (2023)

Prescription stimulant use during long-term opioid therapy and risk for opioid use disorder
por: Scherrer, Jeffrey F., et al.
Publicado: (2022)

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
por: Kunøe, Nikolaj, et al.
Publicado: (2016)

The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature
por: Ramsey, Susan E., et al.
Publicado: (2016)

Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended‐release naltrexone in a residential setting
por: Mannelli, Paolo, et al.
Publicado: (2022)

USL255 extended-release topiramate: Dose-proportional pharmacokinetics and tolerability in healthy volunteers
por: Clark, Annie M, et al.
Publicado: (2014)

Sustained Release of Risedronate from PLGA Microparticles Embedded in Alginate Hydrogel for Treatment of Bony Lesions
por: Azari, Ghazaleh, et al.
Publicado: (2022)

Evaluating predictive relationships between wristbands and urine for assessment of personal PAH exposure
por: Dixon, Holly M., et al.
Publicado: (2022)

Opportunities to expand postpartum support for those in recovery from opioid use disorder: Results from a qualitative study
por: Allen, Alicia, et al.
Publicado: (2023)

The relationship between patient satisfaction and visual and optical outcome after bilateral implantation of an extended depth of focus multifocal intraocular lens
por: Miháltz, Kata, et al.
Publicado: (2022)

HIV clinic‐based extended‐release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non‐blinded, randomized non‐inferiority trial
por: Korthuis, P. Todd, et al.
Publicado: (2022)

Impact of post-release community mental health and disability support on reincarceration for prisoners with intellectual disability and serious mental illness in NSW, Australia
por: Trofimovs, Julian, et al.
Publicado: (2023)

Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone
por: Karlsson, Ann Tarja, et al.
Publicado: (2021)

Factors associated with willingness to take extended release naltrexone among injection drug users
por: Ahamad, Keith, et al.
Publicado: (2015)

Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study
por: Marciuch, Anne, et al.
Publicado: (2022)

Peer recovery coaching for comprehensive HIV, hepatitis C, and opioid use disorder management: The CHORUS pilot study
por: Martin, Anna K., et al.
Publicado: (2023)

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
por: Setnik, Beatrice, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7qs5m5ef6jomt1ucuepvgqaa77